Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Acute Myeloid Leukemia Market Size Forecast: How Large Could The Market Become By 2030?
The Acute Myeloid Leukemia (AML) market witnessed robust expansion recently and is projected to increase from $3.73 billion in 2025 to $3.97 billion in 2026, exhibiting a compound annual growth rate of 6.3%. Factors contributing to this historical growth encompass the increasing incidence of AML, enhancements in healthcare facilities, heightened consciousness surrounding leukemia therapies, the implementation of standard chemotherapy regimens, and the progress made in supportive care strategies.
The market for acute myeloid leukemia is anticipated to experience robust expansion in the forthcoming years, projecting a rise to $5.25 billion by 2030, fueled by a compound annual growth rate (CAGR) of 7.3%. This projected growth throughout the forecast period is largely attributable to significant advancements in targeted therapy drugs, a rise in the frequency of stem cell transplant procedures, the ongoing development of innovative tyrosine kinase inhibitors, the expansion of ambulatory care facilities, and the increasing integration of personalized medicine strategies within treatment protocols. Key trends shaping this period include a heightened adoption of targeted AML therapies, a growing utilization of stem cell transplantation, an increasing demand for individualized chemotherapy regimens, the wider application of tyrosine kinase inhibitors and monoclonal antibodies, and a strengthened emphasis on early detection and ongoing monitoring of AML.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp
#Acute Myeloid Leukemia Market Growth Factors: Which Forces Are Supporting Market Expansion?
The expansion of the acute myeloid leukemia market is anticipated to be significantly boosted by the growing trend towards personalized medicine. This sophisticated medical strategy involves tailoring treatments based on each patient’s unique genetic makeup, environmental influences, and lifestyle choices. Within the context of acute myeloid leukemia, personalized medicine leverages molecular profiling to pinpoint the specific genetic alterations and biomarkers present in individual patients. This detailed understanding then informs the choice of targeted therapies and customized treatment regimens, thereby enhancing treatment efficacy and reducing unwanted side effects, leading to a more individualized and exact method of managing AML. As an illustration, the Personalized Medicine Coalition reported in February 2024 that the FDA greenlit 16 novel personalized treatments for individuals with rare diseases in 2023, a notable increase from the six approvals seen in the preceding year. Consequently, the amplified use of personalized medicine is a key factor fueling the advancement of the acute myeloid leukemia market.
Acute Myeloid Leukemia Market Segmentation Trends And Revenue Drivers
The acute myeloid leukemia market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Stem Cell Transplant, Targeted Therapy
2) By Treatment Phase: Induction Therapy, Consolidation Therapy, Maintenance Therapy, Relapsed Or Refractory Therapy
3) By End-User: Hospitals, Specialty Oncology Centers, Transplant Centers, Research and Academic Institutes
Subsegments:
1) By Chemotherapy: Cytarabine-Based Therapy, Anthracycline-Based Therapy, Hypomethylating Agents, Low-Intensity Chemotherapy, Combination Chemotherapy Regimens
2) By Stem Cell Transplant: Allogeneic Stem Cell Transplant, Autologous Stem Cell Transplant, Conditioning Regimens, Post-Transplant Maintenance Therapy
3) By Targeted Therapy: FLT3 Inhibitors, IDH1 Inhibitors, IDH2 Inhibitors, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, Other Targeted Agents
Acute Myeloid Leukemia Market Industry Trends: What Changes Are Reshaping Demand?
Leading entities within the acute myeloid leukemia sector are prioritizing the creation of sophisticated therapeutic options, including maintenance monotherapy, to broaden their offerings, enhance patient results, and tackle existing treatment gaps. Maintenance monotherapy signifies a therapeutic strategy involving the sustained administration of a singular medicinal compound over an extended period to ward off the resurgence or advancement of a specific ailment. Illustrating this, in July 2023, Daiichi Sankyo Company Limited, a pharmaceutical firm headquartered in Japan, secured United States Food and Drug Administration (USFDA) clearance for quizartinib, marketed as Vanflyta, for use alongside conventional cytarabine and anthracycline induction therapy, followed by cytarabine consolidation, and subsequently as maintenance monotherapy, targeting adult patients newly diagnosed with acute myeloid leukemia (AML) who possess the FLT3 internal tandem duplication (ITD) mutation, as identified by an FDA-approved test. Complementing this, the LeukoStrat CDx FLT3 Mutation Assay has also been authorized as a companion diagnostic for Vanflyta. This regulatory milestone stems from favorable outcomes observed in the QuANTUM-First trial, which demonstrated a significant enhancement in overall survival for individuals treated with quizartinib when juxtaposed with a placebo. The prescribed dosage of quizartinib is adjusted across the induction, consolidation, and maintenance stages. It is crucial to note that this drug is not recommended for maintenance monotherapy subsequent to allogeneic hematopoietic stem cell transplantation.
#Acute Myeloid Leukemia Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.
Access The Complete Acute Myeloid Leukemia Market Report:
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Acute Myeloid Leukemia Market Regional Distribution: Which Areas Drive Market Expansion?
North Americawas the largest region in the acute myeloid leukemia market in 2025. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
